DSRM-3716
Based on 10 publication(s) in Google Scholar
DSRM-3716 (5-Iodoisoquinoline) is a potent and selective SARM1 NADase inhibitor with an IC50 of 75 nM. DSRM-3716 is selective against other NAD+-processing enzymes, receptors, and transporters. DSRM-3716 provides robust axon protection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.91%
- CAS No.: 58142-99-7
- Formule: C9H6IN
- Masse moléculaire:255.06
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Pattern Recognition Receptors Library
HY-L237
Publications Citing Use of MedChemExpress (MCE) DSRM-3716
More- Immunity. 2026 Mar 6:S1074-7613(26)00040-3. [Abstract]
- Neuron. 2026 Apr 16:S0896-6273(26)00218-7. [Abstract]
- Nat Chem Biol. 2025 Aug 22. [Abstract]
- Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
- Cell Rep Med. 2024 Feb 20;5(2):101400. [Abstract]
- Chem Eng J. 2024 Aug 15.
- Int Immunopharmacol. 2024 Jun 15:134:112193. [Abstract]
- Mol Brain. 2025 Nov 21;18(1):87. [Abstract]
- bioRxiv. 2024 November 25.
- SSRN. 2024 Feb 14.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
Flow Cytometry
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
Activité biologique
IC50: 75 nM (SARM1 NADase)[1]
DSRM-3716 treatment produces dose-dependent inhibition of cADPR increase (IC50 of 2.8 μM) and substantial preservation of NAD+ in these cultures in a manner consistent with engagement and inhibition of SARM1 enzymatic NADase activity inside the cells[1].
DSRM-3716 prevents neurofilament light chain (NfL) release from severed axons in a dose-dependent manner, with an IC50 of ~2 μM[1].
The potency of DSRM-3716 to inhibit cADPR increase caused by axotomy (IC50 of 2.8 μM) is similar to the potency required to prevent axonal degeneration (IC50 of 2.1 μM)[1].
DSRM-3716 inhibits the SARM1-dependent cell destruction pathway triggered by Rotenone in sensory neurons[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 58142-99-7
-
Appearance Solid
-
Masse moléculaire 255.06
-
Formule C9H6IN
-
Color Yellow to brown
-
SMILES
IC1=CC=CC2=C1C=CN=C2
-
Synonyms
5-Iodoisoquinoline
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Macrophage metabolic exhaustion and PANoptotic cell death drive chronic tissue inflammation in rheumatoid arthritis. [Abstract]2026 Mar 6:S1074-7613(26)00040-3. PMID: 41794034
DSRM-3716 purchased from MedChemExpress. Usage Cited in: Immunity. 2026 Mar 6:S1074-7613(26)00040-3. [Abstract]
DSRM-3716 (2mg/kg; i.p.; every other day for 12 d) diminished the density of CD3+ T cells and minimized IL-6 production in synovial fibroblasts of NSG mice.
DSRM-3716 purchased from MedChemExpress. Usage Cited in: Immunity. 2026 Mar 6:S1074-7613(26)00040-3. [Abstract]
DSRM-3716 (2mg/kg; i.p.; every other day for 12 d) efficiently reduced inflammation scores of NSG mice under conditions of C1q-exacerbated synovitis.
DSRM-3716 purchased from MedChemExpress. Usage Cited in: Immunity. 2026 Mar 6:S1074-7613(26)00040-3. [Abstract]
DSRM-3716 (2mg/kg; i.p.; every other day for 12 d) decreased the death rate of MerTK+CD206+ macrophages by 50% in NSG mice.
DSRM-3716 purchased from MedChemExpress. Usage Cited in: Immunity. 2026 Mar 6:S1074-7613(26)00040-3. [Abstract]
DSRM-3716 (2 mg/kg; i.p.; every other day for 12 d) recovered CSFEneg macrophages in NSG mice.
-
Neuron
2026 Apr 16:S0896-6273(26)00218-7. PMID: 41997149 -
Nat Chem Biol
2025 Aug 22. PMID: 40846996 -
Acta Pharm Sin B
Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis. [Abstract]2025 Sep;15(9):4789-4806. PMID: 41049740
DSRM-3716 purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Sep;15(9):4789-4806. [Abstract]
DSRM-3716 (1.4 μM) reduced cell viability in SARM1 overexpression NMCFs.
-
Cell Rep Med
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. [Abstract]2024 Feb 20;5(2):101400. PMID: 38307031 -
-
Int Immunopharmacol
Inhibiting the SARM1-NAD+ axis reduces oxidative stress-induced damage to retinal and nerve cells. [Abstract]2024 Jun 15:134:112193. PMID: 38723372 -
Mol Brain
Deficiency of SARM1 attenuates neuronal injury and improves neurological performance in a photothrombotic stroke model. [Abstract]2025 Nov 21;18(1):87. PMID: 41272776 -
-
Solvant et solubilité
DMSO : 50 mg/mL (196.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (421 KB)
- English - EN (421 KB)
- Français - FR (421 KB)
- Deutsch - DE (421 KB)
- Norwegian - NO (421 KB)
- Español - ES (421 KB)
- Swedish - SV (421 KB)
- Italian - IT (421 KB)
- Korean - KR (421 KB)
- Portuguese - PT (421 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9207 mL | 19.6034 mL | 39.2068 mL | 98.0169 mL |
| 5 mM | 0.7841 mL | 3.9207 mL | 7.8414 mL | 19.6034 mL | |
| 10 mM | 0.3921 mL | 1.9603 mL | 3.9207 mL | 9.8017 mL | |
| 15 mM | 0.2614 mL | 1.3069 mL | 2.6138 mL | 6.5345 mL | |
| 20 mM | 0.1960 mL | 0.9802 mL | 1.9603 mL | 4.9008 mL | |
| 25 mM | 0.1568 mL | 0.7841 mL | 1.5683 mL | 3.9207 mL | |
| 30 mM | 0.1307 mL | 0.6534 mL | 1.3069 mL | 3.2672 mL | |
| 40 mM | 0.0980 mL | 0.4901 mL | 0.9802 mL | 2.4504 mL | |
| 50 mM | 0.0784 mL | 0.3921 mL | 0.7841 mL | 1.9603 mL | |
| 60 mM | 0.0653 mL | 0.3267 mL | 0.6534 mL | 1.6336 mL | |
| 80 mM | 0.0490 mL | 0.2450 mL | 0.4901 mL | 1.2252 mL | |
| 100 mM | 0.0392 mL | 0.1960 mL | 0.3921 mL | 0.9802 mL |
DSRM-3716 Related Classifications
HY-W021879 Related Classifications
Powered by Bioz